Top

Published in:

01-02-2020 | Type 2 Diabetes | Original Article

Serum complement C3 and islet β-cell function in patients with type 2 diabetes: A 4.6-year prospective follow-up study

Authors: Jian-bin Su, Yun-Yu Wu, Feng Xu, Xing Wang, Hong-li Cai, Li-hua Zhao, Xiu-lin Zhang, Tong Chen, Hai-yan Huang, Xue-qin Wang

Published in: Endocrine | Issue 2/2020

Abstract

Purpose

Serum complement C3 has been shown to contribute to the incidence of type 2 diabetes (T2D), but how serum complement C3 affects islet β-cell function throughout the course of T2D is unclear. This study explored whether serum complement C3 is independently associated with changes in islet β-cell function over time in patients with T2D.

Methods

Serum complement C3 was measured, and endogenous β-cell function was evaluated by area under the C-peptide curve (AUC_cp) during an oral glucose tolerance test (OGTT) in 411 patients with T2D at baseline from 2011 to 2015. Next, 347 of those patients with available data were pooled for a final follow-up analysis from 2014 to 2018. Changes in islet β-cell function at follow-up were evaluated by AUC_cp percentage changes (ΔAUC_cp%). In addition, other possible clinical risks for diabetes were also examined.

Results

The 347 patients included in the analysis had a diabetes duration of 4.84 ± 3.63 years at baseline. Baseline serum complement C3 (baseline C3) levels were positively correlated with baseline natural logarithm of AUC_cp (lnAUC_cp) (n = 347, r = 0.288, p < 0.001), and baseline C3 was independently associated with baseline lnAUC_cp (β = 0.17, t = 3.52, p < 0.001) after adjustment for baseline glycemic status and other clinical confounders by multivariate liner regression analysis. Compared with the baseline values, complement C3 changes (ΔC3) and ΔAUC_cp% was –0.15 ± 0.28 mg/ml and –17.2 ± 18.4%, respectively, at a follow-up visit 4.57 ± 0.78 years later. Moreover, ΔC3 was positively correlated with ΔAUC_cp% (n = 347, r = 0.302, p < 0.001). Furthermore, each 0.1 mg/ml increase in ΔC3 was associated with a higher ΔAUC_cp% (1.41% [95% CI, 0.82–2.00%]) after adjusting for changes in glycemic status and other clinical confounders at follow-up.

Conclusions

In addition to serum complement C3 being independently associated with islet β-cell function at baseline, its changes were also independently associated with changes in islet β-cell function over time in patients with T2D.

Available only for authorised users

B.L. Wajchenberg, beta-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 28(2), 187–218 (2007). https://doi.org/10.1210/10.1210/er.2006-0038 CrossRefPubMed

R.C. Tubner, C.A. Cull, R.R. Holman, U.K. prospective diabetes study. Diabetes Care 19(2), 182–183 (1996)CrossRef

M.Y. Donath, S.E. Shoelson, Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11(2), 98–107 (2011). https://doi.org/10.1038/nri2925 CrossRefPubMed

J. Rojas, V. Bermudez, J. Palmar, M.S. Martinez, L.C. Olivar, M. Nava, D. Tomey, M. Rojas, J. Salazar, C. Garicano, M. Velasco, Pancreatic beta cell death: novel potential mechanisms in diabetes therapy. J. Diabetes Res. 2018, 9601801 (2018). https://doi.org/10.1155/2018/9601801 CrossRefPubMedPubMedCentral

N.S. Merle, S.E. Church, V. Fremeaux-Bacchi, L.T. Roumenina, Complement system part I—molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015). https://doi.org/10.3389/fimmu.2015.00262 CrossRefPubMedPubMedCentral

D. Ricklin, G. Hajishengallis, K. Yang, J.D. Lambris, Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11(9), 785–797 (2010). https://doi.org/10.1038/ni.1923 CrossRefPubMedPubMedCentral

J.M. Moreno-Navarrete, J.M. Fernandez-Real, The complement system is dysfunctional in metabolic disease: Evidences in plasma and adipose tissue from obese and insulin resistant subjects. Semin. Cell Dev. Biol. 85, 164–172 (2019). https://doi.org/10.1016/j.semcdb.2017.10.025 CrossRefPubMed

G. Bajic, S.E. Degn, S. Thiel, G.R. Andersen, Complement activation, regulation, and molecular basis for complement-related diseases. Embo. J. 34(22), 2735–2757 (2015). https://doi.org/10.15252/embj.201591881 CrossRefPubMedPubMedCentral

E. Hertle, M.M. van Greevenbroek, C.D. Stehouwer, Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 55(4), 881–884 (2012). https://doi.org/10.1007/s00125-012-2462-z CrossRefPubMedPubMedCentral

10.

X. Bao, Y. Xia, Q. Zhang, H.M. Wu, H.M. Du, L. Liu, C.J. Wang, H.B. Shi, X.Y. Guo, X. Liu, C.L. Li, Q. Su, G. Meng, B. Yu, S.M. Sun, X. Wang, M. Zhou, Q.Y. Jia, K. Song, K.J. Niu, Elevated serum complement C3 levels are related to the development of prediabetes in an adult population: the Tianjin Chronic Low-Grade Systematic Inflammation and Health Cohort Study. Diabet. Med. 33(4), 446–453 (2016). https://doi.org/10.1111/dme.12827 CrossRefPubMed

11.

G. Engstrom, B. Hedblad, K.F. Eriksson, L. Janzon, F. Lindgarde, Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54(2), 570–575 (2005)CrossRef

12.

J. Phieler, R. Garcia-Martin, J.D. Lambris, T. Chavakis, The role of the complement system in metabolic organs and metabolic diseases. Semin. Immunol. 25(1), 47–53 (2013). https://doi.org/10.1016/j.smim.2013.04.003 CrossRefPubMedPubMedCentral

13.

J. Sjolander, G.T. Westermark, E. Renstrom, A.M. Blom, Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation. J. Biol. Chem. 287(14), 10824–10833 (2012). https://doi.org/10.1074/jbc.M111.244285 CrossRefPubMedPubMedCentral

14.

S. He, C. Atkinson, F. Qiao, K. Cianflone, X. Chen, S. Tomlinson, A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J. Clin. Investig. 119(8), 2304–2316 (2009). https://doi.org/10.1172/jci38289 CrossRefPubMed

15.

American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1), S62–S69 (2011). https://doi.org/10.2337/dc11-S062 CrossRefPubMedCentral

16.

T. Radaelli, K.A. Farrell, L. Huston-Presley, S.B. Amini, J.P. Kirwan, H.D. McIntyre, P.M. Catalano, Estimates of insulin sensitivity using glucose and C-Peptide from the hyperglycemia and adverse pregnancy outcome glucose tolerance test. Diabetes Care 33(3), 490–494 (2010). https://doi.org/10.2337/dc09-1463 CrossRefPubMed

17.

L. Zhao, J. Ma, S. Wang, Y. Xie, Relationship between beta-cell function, metabolic control, and microvascular complications in type 2 diabetes mellitus. Diabetes Technol. Ther. 17(1), 29–34 (2015). https://doi.org/10.1089/dia.2014.0214 CrossRefPubMed

18.

L.A. Inker, C.H. Schmid, H. Tighiouart, J.H. Eckfeldt, H.I. Feldman, T. Greene, J.W. Kusek, J. Manzi, F. Van Lente, Y.L. Zhang, J. Coresh, A.S. Levey, Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367(1), 20–29 (2012). https://doi.org/10.1056/NEJMoa1114248 CrossRefPubMedPubMedCentral

19.

J.J. Meier, B.A. Menge, T.G. Breuer, C.A. Muller, A. Tannapfel, W. Uhl, W.E. Schmidt, H. Schrader, Functional assessment of pancreatic beta-cell area in humans. Diabetes 58(7), 1595–1603 (2009). https://doi.org/10.2337/db08-1611 CrossRefPubMedPubMedCentral

20.

J.M. Fernandez-Real, G. Penarroja, A. Castro, F. Garcia-Bragado, I. Hernandez-Aguado, W. Ricart, Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 51(4), 1000–1004 (2002)CrossRef

21.

A. Mallipedhi, T. Min, S.L. Prior, C. MacIver, S.D. Luzio, G. Dunseath, R.M. Bracken, S. Islam, J.D. Barry, S. Caplin, J.W. Stephens, Association between the preoperative fasting and postprandial C-peptide AUC with resolution of type 2 diabetes 6 months following bariatric surgery. Metabolism 64(11), 1556–1563 (2015). https://doi.org/10.1016/j.metabol.2015.08.009 CrossRefPubMed

22.

H. Tfayli, F. Bacha, N. Gungor, S. Arslanian, Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two? Diabetes Care 33(3), 632–638 (2010). https://doi.org/10.2337/dc09-0305 CrossRefPubMed

23.

P. Rowe, C. Wasserfall, B. Croker, M. Campbell-Thompson, A. Pugliese, M. Atkinson, D. Schatz, Increased complement activation in human type 1 diabetes pancreata. Diabetes Care 36(11), 3815–3817 (2013). https://doi.org/10.2337/dc13-0203 CrossRefPubMedPubMedCentral

24.

A. Klegeris, P.L. McGeer, Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. Biochem. Biophys. Res. Commun. 357(4), 1096–1099 (2007). https://doi.org/10.1016/j.bbrc.2007.04.055 CrossRefPubMed

25.

Y. Mamane, C. Chung Chan, G. Lavallee, N. Morin, L.J. Xu, J. Huang, R. Gordon, W. Thomas, J. Lamb, E.E. Schadt, B.P. Kennedy, J.A. Mancini, The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 58(9), 2006–2017 (2009). https://doi.org/10.2337/db09-0323 CrossRefPubMedPubMedCentral

26.

J.C. McNelis, J.M. Olefsky, Macrophages, immunity, and metabolic disease. Immunity 41(1), 36–48 (2014). https://doi.org/10.1016/j.immuni.2014.05.010 CrossRefPubMed

27.

W. Quan, E.K. Jo, M.S. Lee, Role of pancreatic beta-cell death and inflammation in diabetes. Diabetes Obes. Metab. 15(Suppl 3), 141–151 (2013). https://doi.org/10.1111/dom.12153 CrossRefPubMed

28.

S.S. Rensen, Y. Slaats, A. Driessen, C.J. Peutz-Kootstra, J. Nijhuis, R. Steffensen, J.W. Greve, W.A. Buurman, Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 50(6), 1809–1817 (2009). https://doi.org/10.1002/hep.23228 CrossRefPubMed

29.

H. Esterbauer, F. Krempler, H. Oberkofler, W. Patsch, The complement system: a pathway linking host defence and adipocyte biology. Eur. J. Clin. Investig. 29(8), 653–656 (1999)CrossRef

30.

Z. Liu, Q. Tang, J. Wen, Y. Tang, D. Huang, Y. Huang, J. Xie, Y. Luo, M. Liang, C. Wu, Z. Lu, A. Tan, Y. Gao, Q. Wang, Y. Jiang, Z. Yao, X. Lin, H. Zhang, Z. Mo, X. Yang, Elevated serum complement factors 3 and 4 are strong inflammatory markers of the metabolic syndrome development: a longitudinal cohort study. Sci. Rep. 6, 18713 (2016). https://doi.org/10.1038/srep18713 CrossRefPubMedPubMedCentral

31.

N. Wlazlo, M.M. van Greevenbroek, I. Ferreira, E.J. Feskens, C.J. van der Kallen, C.G. Schalkwijk, B. Bravenboer, C.D. Stehouwer, Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care 37(7), 1900–1909 (2014). https://doi.org/10.2337/dc13-2804 CrossRefPubMed

32.

K.L. Rasmussen, B.G. Nordestgaard, S.F. Nielsen, Complement C3 and risk of diabetic microvascular disease: a cohort study of 95,202 individuals from the general population. Clin. Chem. 64(7), 1113–1124 (2018). https://doi.org/10.1373/clinchem.2018.287581 CrossRefPubMed

33.

G. Engstrom, B. Hedblad, L. Janzon, F. Lindgarde, Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur. J. Cardiovasc. Prev. Rehabil. 14(3), 392–397 (2007). https://doi.org/10.1097/01.hjr.0000244582.30421.b2 CrossRefPubMed

34.

I.U. Schraufstatter, R.G. Discipio, M. Zhao, S.K. Khaldoyanidi, C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J. Immunol. 182(6), 3827–3836 (2009). https://doi.org/10.4049/jimmunol.0803055 CrossRefPubMed

35.

N. Matsumoto, A. Satyam, M. Geha, P.H. Lapchak, J.J. Dalle Lucca, M.G. Tsokos, G.C. Tsokos, C3a enhances the formation of intestinal organoids through C3aR1. Front. Immunol. 8, 1046 (2017). https://doi.org/10.3389/fimmu.2017.01046 CrossRefPubMedPubMedCentral

36.

T. Haynes, A. Luz-Madrigal, E.S. Reis, N.P. Echeverri Ruiz, E. Grajales-Esquivel, A. Tzekou, P.A. Tsonis, J.D. Lambris, K. Del Rio-Tsonis, Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. Nat. Commun. 4, 2312 (2013). https://doi.org/10.1038/ncomms3312 CrossRefPubMedPubMedCentral

37.

C.W. Strey, M. Markiewski, D. Mastellos, R. Tudoran, L.A. Spruce, L.E. Greenbaum, J.D. Lambris, The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198(6), 913–923 (2003). https://doi.org/10.1084/jem.20030374 CrossRefPubMedPubMedCentral

38.

M.M. Markiewski, D. Mastellos, R. Tudoran, R.A. DeAngelis, C.W. Strey, S. Franchini, R.A. Wetsel, A. Erdei, J.D. Lambris, C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J. Immunol. 173(2), 747–754 (2004). https://doi.org/10.4049/jimmunol.173.2.747 CrossRefPubMed

39.

T.V. Fiorentino, M.L. Hribal, F. Andreozzi, M. Perticone, A. Sciacqua, F. Perticone, G. Sesti, Plasma complement C3 levels are associated with insulin secretion independently of adiposity measures in non-diabetic individuals. Nutr. Metab. Cardiovasc. Dis. 25(5), 510–517 (2015). https://doi.org/10.1016/j.numecd.2015.02.007 CrossRefPubMed

40.

R.S. Dos Santos, L. Marroqui, F.A. Grieco, L. Marselli, M. Suleiman, S.R. Henz, P. Marchetti, R. Wernersson, D.L. Eizirik, Protective role of complement C3 against cytokine-mediated beta-cell apoptosis. Endocrinology 158(8), 2503–2521 (2017). https://doi.org/10.1210/en.2017-00104 CrossRefPubMedPubMedCentral

41.

B.C. King, K. Kulak, U. Krus, R. Rosberg, E. Golec, K. Wozniak, M.F. Gomez, E. Zhang, D.J. O’Connell, E. Renstrom, A.M. Blom, Complement component C3 is highly expressed in human pancreatic islets and prevents beta cell death via ATG16L1 interaction and autophagy regulation. Cell Metab. 29(1), 202–210.e206 (2019). https://doi.org/10.1016/j.cmet.2018.09.009 CrossRefPubMed

42.

B. Ahren, P.J. Havel, G. Pacini, K. Cianflone, Acylation stimulating protein stimulates insulin secretion. Int. J. Obes. Relat. Metab. Disord. 27(9), 1037–1043 (2003). https://doi.org/10.1038/sj.ijo.0802369 CrossRefPubMed

43.

J.C. Lo, S. Ljubicic, B. Leibiger, M. Kern, I.B. Leibiger, T. Moede, M.E. Kelly, D. Chatterjee Bhowmick, I. Murano, P. Cohen, A.S. Banks, M.J. Khandekar, A. Dietrich, J.S. Flier, S. Cinti, M. Bluher, N.N. Danial, P.O. Berggren, B.M. Spiegelman, Adipsin is an adipokine that improves beta cell function in diabetes. Cell 158(1), 41–53 (2014). https://doi.org/10.1016/j.cell.2014.06.005 CrossRefPubMedPubMedCentral

44.

M. Kolev, G. Le Friec, C. Kemper, Complement–tapping into new sites and effector systems. Nat. Rev. Immunol. 14(12), 811–820 (2014). https://doi.org/10.1038/nri3761 CrossRefPubMed

45.

M. Wysoczynski, M. Solanki, S. Borkowska, P. van Hoose, K.R. Brittian, S.D. Prabhu, M.Z. Ratajczak, G. Rokosh, Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction. Stem Cells 32(9), 2502–2515 (2014). https://doi.org/10.1002/stem.1743 CrossRefPubMedPubMedCentral

46.

Y. Rahpeymai, M.A. Hietala, U. Wilhelmsson, A. Fotheringham, I. Davies, A.K. Nilsson, J. Zwirner, R.A. Wetsel, C. Gerard, M. Pekny, M. Pekna, Complement: a novel factor in basal and ischemia-induced neurogenesis. Embo. J. 25(6), 1364–1374 (2006). https://doi.org/10.1038/sj.emboj.7601004 CrossRefPubMedPubMedCentral

47.

Y. Ma, Y. Liu, Z. Zhang, G.Y. Yang, Significance of complement system in ischemic stroke: a comprehensive review. Aging Dis. 10(2), 429–462 (2019). https://doi.org/10.14336/ad.2019.0119 CrossRefPubMedPubMedCentral

Title: Serum complement C3 and islet β-cell function in patients with type 2 diabetes: A 4.6-year prospective follow-up study
Authors: Jian-bin Su
Yun-Yu Wu
Feng Xu
Xing Wang
Hong-li Cai
Li-hua Zhao
Xiu-lin Zhang
Tong Chen
Hai-yan Huang
Xue-qin Wang
Publication date: 01-02-2020
Publisher: Springer US
Keyword: Type 2 Diabetes
Published in: Endocrine / Issue 2/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02144-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis

Calcitonin as a biomarker of C cell disease: recent achievements and current challenges

Associations of apnea hypopnea index and educational attainments with microvascular complications in patients with T2DM

Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?

Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro

Sex-related differences in self-care behaviors of adults with type 2 diabetes mellitus

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage